论文部分内容阅读
皮卡佐剂狂犬病疫苗已取得国家临床研究批件。在暴露后免疫中,即使未同时接种抗血清,皮卡佐剂狂犬病疫苗也具有良好的保护效果,明显优于无佐剂的市售疫苗。因此,皮卡佐剂狂犬病疫苗有可能发展为一种治疗性疫苗,在无法实施抗血清接种时,用于Ⅲ度暴露后咬伤患者的免疫。本文就有关该疫苗的有效性作一综述,包括皮卡佐剂狂犬病疫苗的非特异性免疫功能及在动物体内的体液免疫和细胞免疫应答。
Picatin adjuvant rabies vaccine has made the national clinical research approved. In post-exposure immunization, the Picucapto-based rabies vaccine has a good protective effect, even though it is not administered simultaneously, clearly superior to the commercial vaccine without adjuvant. As a result, the Picaka adjuvant rabies vaccine is likely to develop as a therapeutic vaccine for immunization of patients with post-exposure bite when antisera can not be administered. This article reviews the effectiveness of the vaccine, including the nonspecific immune function of the Picaka adjuvant rabies vaccine and its humoral and cellular immune responses in animals.